Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor

Oncogene

Volumn 34, Issue 21, 2015, Pages 2807-2813

  Voce, D J ^a   Schmitt, A M ^a   Uppal, A ^a   McNerney, M E ^b   Bernal, G M ^a   Cahill, K E ^a   Wahlstrom, J S ^a   Nassiri, A ^a   Yu, X ^a   Crawley, C D ^a   White, K P ^b   Onel, K ^a   Weichselbaum, R R ^a   Yamini, B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DNA; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NUCLEAR FACTOR KAPPA B1; PROTEIN P50; UNCLASSIFIED DRUG; NFKB1 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALKYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LEUKEMIA; CANCER INHIBITION; CARCINOGENESIS; CELL DEATH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DNA BINDING; DNA DAMAGE; DNA STRAND BREAKAGE; DOWN REGULATION; EMBRYO; FEMALE; FUNCTIONAL STATUS; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GENETIC ANALYSIS; GENOMIC INSTABILITY; GENOTYPE; HAPLOINSUFFICIENCY; HETEROZYGOSITY LOSS; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INDUCED MUTATION; IONIZING RADIATION; LARGE CELL LYMPHOMA; MALE; MOUSE; MUTATION RATE; NEXT GENERATION SEQUENCING; NFKB1 GENE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; THYMUS LYMPHOMA; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; C57BL MOUSE; GENETICS; TUMOR CELL CULTURE;

ANIMALIA; MUS;

ALKYLATION; ANIMALS; CELL DEATH; DNA DAMAGE; DOWN-REGULATION; FEMALE; HAPLOINSUFFICIENCY; HETEROZYGOTE; HUMANS; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B P50 SUBUNIT; RADIATION, IONIZING; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84930270917     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.211     Document Type: Article

References (38)

1. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005; 5: 943-955.
2. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J et al. Clinicalcytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 2003; 102: 43-52.
3. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18: 6938-6947.
4. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296.
5. Perkins ND. NF-kappaB: Tumor promoter or suppressor? Trends Cell Biol 2004; 14: 64-69.
6. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003; 421: 639-643.
7. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000; 404: 892-897.
8. Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND. Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. Embo J 2005; 24: 1157-1169.
9. Wolff B, Naumann M. INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappaB. Oncogene 1999; 18: 2663-2666.
10. Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, Ho W et al. Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene 2006; 25: 6781-6799.
11. Schmitt AM, Crawley CD, Kang S, Raleigh DR, Yu X, Wahlstrom JS et al. p50 (NF-kappaB1) is an effector protein in the cytotoxic response to DNA methylation damage. Mol Cell 2011; 44: 785-796.
12. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23: 35-61.
13. Margison GP, Santibanez Koref MF, Povey AC. Mechanisms of carcinogenicity/ chemotherapy by O6-methylguanine. Mutagenesis 2002; 17: 483-487.
14. Joshi VV, Frei JV. Effects of dose and schedule of methylnitrosourea on incidence of malignant lymphoma in adult female mice. J Natl Cancer Inst 1970; 45: 335-339.
15. Dumenco LL, Allay E, Norton K, Gerson SL. The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. Science 1993; 259: 219-222.
16. Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 1995; 80: 321-330.
17. Hoffmann A, Leung TH, Baltimore D. Genetic analysis of NF-kappaB/Rel transcription factors defines functional specificities. Embo J 2003; 22: 5530-5539.
18. Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007; 117: 823-834.
19. Andersson A, Ritz C, Lindgren D, Eden P, Lassen C, Heldrup J et al. Microarraybased classification of a consecutive series of 121 childhood acute leukemias: Prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007; 21: 1198-1203.
20. Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, Kraut N et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004; 22: 3937-3949.
21. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639-1647.
22. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
23. Glauert HP, Eyigor A, Tharappel JC, Cooper S, Lee EY, Spear BT. Inhibition of hepatocarcinogenesis by the deletion of the p50 subunit of NF-kappaB in mice administered the peroxisome proliferator Wy-14,643. Toxicol Sci 2006; 90: 331-336.
24. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665-677.
25. Chang PY, Draheim K, Kelliher MA, Miyamoto S. NFKB1 is a direct target of the TAL1 oncoprotein in human T leukemia cells. Cancer Res 2006; 66: 6008-6013.
26. Li Z, Wang X, Yu RY, Ding BB, Yu JJ, Dai XM et al. BCL-6 negatively regulates expression of the NF-kappaB1 p105/p50 subunit. J Immunol 2005; 174: 205-214.
27. Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL. Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Oncogene 2005; 24: 6231-6240.
28. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13: 35-45.
29. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: Assessment and strategies for risk reduction. J Clin Oncol 2012; 30: 3734-3745.
30. Neyns B, Cordera S, Joosens E, Pouratian N. Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide. J Clin Oncol 2008; 26: 4518-4519.
31. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997; 386: 763.
32. Sherr CJ. Principles of tumor suppression. Cell 2004; 116: 235-246.
33. Yamini B, Yu X, Dolan ME, Wu MH, Darga TE, Kufe DW et al. Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding. Cancer Res 2007; 67: 6889-6898.
34. Olive PL, Banath JP. The comet assay: A method to measure DNA damage in individual cells. Nat Protoc 2006; 1: 23-29.
35. McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood 2013; 121: 975-983.
36. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF et al. NCBI GEO: Archive for functional genomics data sets-10 years on. Nucleic Acids Res 2011; 39: D1005-D1010.
37. Davis S, Meltzer PS. GEOquery: A bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 2007; 23: 1846-1847.
38. Du P, Kibbe WA, Lin SM. lumi: A pipeline for processing Illumina microarray. Bioinformatics 2008; 24: 1547-1548.